9.61
+0.84%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Berry Genomics Co
Its shares trade on Shenzhen under the ticker 000710.SZ. It has been listed since 22 April 1997. In the fiscal year to 31 December 2025, it reported revenue of CN¥929.8m and a net loss of CN¥196.8m. At that date it held total assets of CN¥2.28bn and shareholders' equity of CN¥1.48bn.
Berry Genomics Co., Ltd. engages in the gene detection and sales of equipment and reagents of high-throughput sequencing technology. The company is headquartered in Beijing, Beijing. The firm's business is comprised of basic scientific research services, medical testing services, testing reagent sales and testing equipment sales. The basic scientific research services business provides the clients with multiple sequencing platforms for testing projects, such as transcriptome sequencing, human whole exome sequencing and whole genome sequencing. The medical testing services business include tumor genetic testing services, genetic disease genetic testing services and reproductive health testing services. The firm sells a range of reagents and equipment, including NextSeq CN500 gene sequencer and general reagents for sequencing reactions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Apr 1997
- Employees
- 1,438
- Website
- berrygenomics.com ↗
Leadership
Pay as last reported
- Mr. Yang GaoChairman of the Board, General Manager, since 2017CN¥1.2m
- Mr. Dong WangChief Financial Officer, Deputy General Manager, Director, since 2017CN¥446,300
- Ms. Wenlu AiChief Securities Investment OfficerCN¥578,400
- Mr. Fei XuSecretary of the Board, Chief Investor Relations Officer, since 2024
- Ms. Hongxia WangDirector
- Mr. Hui ZhaoDirectorCN¥33,300
- Mr. Shiyang HuIndependent DirectorCN¥33,300
- Mr. Yao LiIndependent DirectorCN¥80,000
- Mr. Dake ZhangIndependent DirectorCN¥33,300
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Berry Genomics employs 1,438 full-time employees in Beijing for biotechnology services.
- The company offers NextSeq CN500 gene sequencer and reagents for high-throughput sequencing.
- Berry Genomics provides tumor genetic testing and reproductive health testing services.
Weaknesses
- The company's headquarters in Beijing may limit global market access.
- Limited business description focuses on domestic services without international expansion.
- No mention of international partnerships or global market presence.
Opportunities
- Expanding medical testing services into new segments like genetic disease testing.
- Increasing demand for high-throughput sequencing technology in China.
- Growing market for reagent and equipment sales in the biotechnology sector.
Threats
- Competition from other biotechnology firms in the Chinese market.
- Regulatory changes affecting medical testing services in China.
- Economic downturns impacting healthcare spending in China.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.